About Dyax
Dyax is a Healthcare company based in Burlington (United States) founded in 1995, and was acquired by Shire in November 2015. Speciality biopharma company developing novel therapeutics for rare diseases. The company has 151 employees. Dyax offers products and services including Pipeline Products and Rusfertide. Its focus areas include Diversified Pharmaceuticals. Its legal entity is DYAX CORP.
Company details
Dyax was founded in 1995 in Burlington, United States, as a specialty biopharmaceutical company. Operations center on the development and commercialization of therapeutics targeting rare diseases, particularly Hereditary Angioedema (HAE). Kalbitor is utilized for treating acute HAE attacks in patients aged 12 and older, while DX-2930 is advanced for prophylactic HAE treatment. The company was acquired by Shire plc in January 2016 for 5.9 billion.
- Annual Revenue$81.72 M (USD)52as on Dec 31, 2014
- Net Profit-$11.88 M (USD)57as on Dec 31, 2014
- EBITDA-$1.24 M (USD)93as on Dec 31, 2014
- Latest Funding Round$50M (USD), Post-IPO
Aug 2008
- InvestorsTakeda Pharmaceuticals
& 1 more
- Employee Count151
- Acquired byShire
(Nov 2015)
Products & Services of Dyax
Dyax offers a comprehensive portfolio of products and services, including Pipeline Products and Rusfertide.
Develops innovative medicines for various health conditions
Treats Polycythemia Vera in patients through clinical advancements
Funding Insights of Dyax
- Total Rounds 1
- Last Round Post-IPO — $50M
- First Round $50M
(Aug 2008)
- Investors Count 1
All 1 funding rounds of Dyax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2008 | $50M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Dyax
Dyax has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland |
Investor details for Dyax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dyax
7 people are tracked at Dyax (2 in leadership, 5 in team); the tracked headcount is 151.
| Name | Role | Group |
|---|---|---|
Mark Sawyer | Senior Vice President - Technical Operations | Leadership |
Bob Ladner | Chief Technical Officer | Leadership |
Bill Cavanagh | Manager Clinical Development | Team |
Jessica Kenyon | Manager Of Quality Assurance | Team |
Ronnie Hall | Facilities | Team |
Veronica Hunter | Senior QC Analyst | Team |
Sagar Pawar | Sales Manager | Team |
Complete people profiles for Dyax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dyax
4 dated milestones of Dyax across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Dyax is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $50.0M.
- Exit Acquired by Shire.
Web traffic of Dyax
Websites that share an audience with Dyax (dyax.com).
Websites whose visitors overlap most with Dyax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
finance.yahoo.com | finance.yahoo.com | 100% | #205 | – | |
| cubist.com | 96% | View details | |||
| sunovion.com | 69% | 11.4K | #4,229,536 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Dyax (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dyax
Complete news archive for Dyax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dyax
Dyax was founded in 1995 and raised its 1st funding round 13 years after it was founded.
Dyax is headquartered in Burlington, United States. It is registered at Burlington, Vermont, United States.
Dyax has 151 employees.
Annual revenue of Dyax is $81.72M as on Dec 31, 2014.
Dyax was founded in 1995 in Burlington, United States, as a specialty biopharmaceutical company. Operations center on the development and commercialization of therapeutics targeting rare diseases, particularly Hereditary Angioedema (HAE). Kalbitor is utilized for treating acute HAE attacks in patients aged 12 and older, while DX-2930 is advanced for prophylactic HAE treatment. The company was acquired by Shire plc in January 2016 for 5.9 billion.
Dyax offers Pipeline Products and Rusfertide.
Dyax has 2 investors. Key investors include Takeda Pharmaceuticals, and HealthCare Royalty Partners.
Dyax operates through Dyax Corp.
Yes. Dyax was acquired by Shire in November 2015.